Stock Events

Stock Events

Innate Pharma 

$2.23
96
+$0.02+1.13% 09:31 Today

Statistics

Day High
2.21
Day Low
2.2
52W High
2.71
52W Low
1.17
Volume
652
Avg. Volume
-
Mkt Cap
246.3M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17SepExpected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Next
-0.45
-0.3
-0.15
0
Expected EPS
-0.342618
Actual EPS
N/A

Financials

-1,763.17%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.28MRevenue
-57.81MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IPHA. It's not an investment recommendation.
TotalEnergies
21
TTE.PA
Stellantis N.V
13
STLAP.PA
BNP Paribas
12
BNP.PA
Credit Agricole.
12
ACA.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol-Myers Squibb competes in the immuno-oncology space, offering products that could be in direct competition with Innate Pharma's pipeline, particularly in cancer treatment.
Merck
MRK
Mkt Cap376.37B
Merck is known for its strong presence in cancer treatment with Keytruda, competing directly with Innate Pharma's oncology focus.
Roche
RHHBY
Mkt Cap334.28B
Roche operates in similar therapeutic areas as Innate Pharma, including oncology, making it a direct competitor in the development of cancer therapies.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca competes in the oncology sector, including collaborations on drugs that could be in competition with Innate Pharma's developments.
Pfizer
PFE
Mkt Cap159.99B
Pfizer has a broad oncology portfolio that competes with Innate Pharma's cancer treatment and research efforts.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences, with its focus on oncology and inflammatory diseases, competes in areas of interest to Innate Pharma.
Novartis
NVS
Mkt Cap301.95B
Novartis has a significant presence in the oncology market, directly competing with Innate Pharma's research and drug development.
AMGEN
AMGN
Mkt Cap237.52B
Amgen's focus on innovative therapeutics in oncology and other areas makes it a competitor to Innate Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on oncology and other areas relevant to Innate Pharma's interests.
Incyte
INCY
Mkt Cap25.91B
Incyte operates in the oncology and inflammation sectors, directly competing with Innate Pharma in the development of treatments for cancer and autoimmune diseases.

About

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Show more...
CEO
Jonathan E. Dickinson
Employees
163
Country
France
ISIN
US45781K2042
WKN
000A2PSSH

Listings

XETRA
DE
IDD.XETRA
STU
DE
IDDA.STU
STU
DE
IDD.STU
LSE
GB
0EVI.LSE

0 Comments

Share your thoughts

FAQ

What is Innate Pharma stock price today?▼
The current price of IPHA is $2.23 USD — it has increased by +1.13% in the past 24 hours. Watch Innate Pharma stock price performance more closely on the chart.
What is Innate Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Innate Pharma stocks are traded under the ticker IPHA.
Is Innate Pharma stock price growing?▼
IPHA stock has risen by +6.52% compared to the previous week, the month change is a +23.88% rise, over the last year Innate Pharma has showed a -1.56% decrease.
What is Innate Pharma market cap?▼
Today Innate Pharma has the market capitalization of 246.3M
When is the next Innate Pharma earnings date?▼
Innate Pharma is going to release the next earnings report on September 17, 2026.
What were Innate Pharma earnings last quarter?▼
IPHA earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.35 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Innate Pharma revenue for the last year?▼
Innate Pharma revenue for the last year amounts to 3.28M USD.
What is Innate Pharma net income for the last year?▼
IPHA net income for the last year is -57.81M USD.
How many employees does Innate Pharma have?▼
As of August 25, 2026, the company has 163 employees.
In which sector is Innate Pharma located?▼
Innate Pharma operates in the Health & Wellness sector.
When did Innate Pharma complete a stock split?▼
Innate Pharma has not had any recent stock splits.
Where is Innate Pharma headquartered?▼
Innate Pharma is headquartered in Marseille, France.